FLUO Share Price Performance
SEK 33.20
-8.10 (-19.61%)
73.1% undervalued intrinsic discount
SEK 123.50
Fair Value
Price SEK 33.20
AnalystConsensusTarget SEK 123.50
Fair ValueSEK 123.50
Share Pricen/a
FluoGuide A/S Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
FLUO Community Narratives
AN
Fair Value SEK 123.5 73.1% undervalued intrinsic discount
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
Catalysts About FluoGuide FluoGuide develops imaging agents that light up cancer during surgery to help surgeons remove tumors more precisely. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
SEK 123.5
73.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
73.65%
Future PE
17.42x
Price in 2029
SEK 144.69
Trending Discussion
Recently Updated Narratives
AN
Regulatory Alignment And Phase II Success Will Support A Wider Surgical Imaging Opportunity
Fair Value: SEK 123.5 73.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
FluoGuide A/S Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 27, 2026
- -2.41
- 100.00%
- -17,935.91%
- 50.6%
About FLUO
- Founded
- 2018
- Employees
- 7
- CEO
- WebsiteView website
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
